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HONORS CAPSTONE ABSTRACT
This project is focused on the recovery rates of patients diagnosed with COVID-19 after
different clinical trial drug treatments. Data for the clinical trial studied was obtained from the
National Institute of Allergy and Infectious Diseases for the primary purpose of a survival
analysis on patient time to recovery under a placebo and therapeutic drug treatment. Specifically,
patients in this clinical trial were randomly selected to receive remdesivir, an antiviral drug, in
combination with a placebo or baricitinib, a janus kinase inhibitor drug. Cox PH models were
used to identify how the different treatment drugs affect time to recovery and time to death,
along with what other patient factors may have an association with both time to recovery and
time to death. It was found that the combination of remdesivir and baricitinib yields a faster
recovery time than using remdesivir alone for treatment. Research on clinical trial drugs is vital
for discovering possible treatments for widespread diseases such as the COVID-19 pandemic.
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Introduction
From the onset of coronavirus disease 2019 (COVID-19), it has become apparent how illequipped healthcare around the world was prepared to deal with a pandemic of this nature. Much
difficulty has been had in preventing the spread of COVID-19 and accommodating the needs of
patients diagnosed with the disease. Part of this difficulty can be attributed to a lack of treatment
options and cures available for the disease. In order to determine the effects of different
treatment options or cures, clinical trial testing must be performed before any treatment options
can be released to the widespread public. Clinical trials deal with the testing of different
treatment options that are thought to be viable options for helping those suffering from a disease.
In clinical trials, what is of main interest is how a patient responds to the treatment, and how
survival of the patient from the disease is impacted with treatment.
To investigate the effects of different factors on a patient’s survival, a common statistical
technique for patient data in the biomedical field is survival analysis. Survival analysis is a data
analysis approach that can answer questions on the probability of an event occurring. Typically,
a time to event variable is required for a survival analysis to be conducted, and it is common that
the event chosen is patient death, although the particular event can be specified as something
other than death. Survival analysis has the capability of determining if certain characteristics
affect survival rates in a population. This technique is then of great use for data involving the
same time to event outcome for different populations. In this study, we would like to investigate
how different populations’ survival rates of COVID-19 are impacted by patient clinical trial
treatments and different patient characteristics.
In particular, of interest in this study is how a patient’s recovery time is impacted not
only by the usage of clinical trial drugs, but also by patient characteristics such as sex, age,
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race/ethnicity, and comorbidities. It has been shown in other survival analyses that these
characteristics can play a role in patient deaths related to COVID-19 (Lu et al., 2021; SalinasEscudero et al., 2020; Thai et al., 2020). Our time to event variable will measure the time to
recovery and our analysis will seek to identify what characteristics assist with patient recovery,
particularly as it relates to different clinical trial drug treatments.
Data
The data in this research was obtained from the National Institute of Allergy and
Infectious Diseases’ (NIAID) sponsored clinical trial study titled “Adaptive COVID-19
Treatment Trial 2” (ACTT-2). The dataset contains patient level data for hospitalized adults
infected with COVID-19. Patients in ACTT-2 were separated into a trial group and a placebo
group to test the effects of therapeutic drugs on recovery time. This clinical trial specifically
sought information on the advantages of using two therapeutic drugs, remdesivir and baricitinib,
in conjunction versus using remdesivir alone. Remdesivir is an antiviral drug that has been
previously authorized by the Food and Drug Administration as a treatment for COVID-19 after
analyses done in NIAID’s sponsored “Adaptive COVID-19 Treatment Trial 1” (FDA, 2020B;
ACTT-1 Study Group, 2020). Baricitinib is a janus kinase inhibitor that helps to decrease the
activity of an overactive immune system and is commonly used for patients with rheumatoid
arthritis for its inflammation blocking properties (FDA, 2020A).
In total, 1,033 patients diagnosed with moderate or severe cases of COVID-19 were
randomly split into a combination drug treatment group (515 patients) and a remdesivir plus
placebo drug treatment group (518 patients). The data received contained information not only
on patient treatment type, but also on other patient characteristics such as age, race, ethnicity,
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sex, BMI, region, etc. and noted a patient’s recovery, recovery time, along with death, and death
time. In both events of death and recovery, the event was indicated as happening with a “0” and
censorship, or the event not occurring, was indicated with a “1.” This censorship variable is what
will be primarily used when conducting model fitting to assess time to recovery and time to
death relationships. A more detailed breakdown of patient data included in the ACTT-2 files
used for this analysis is specified in Appendix Figure 1.
Methods
As the primary focus of this research is to investigate the relationships that exist between
patient recovery and explanatory variables of interest, we must assess any relationships that exist
using statistical modeling techniques. For our analysis, there are three main steps involved with
fitting these statistical models. The first step is to fit Kaplan-Meier curves, which are created
from non-parametric estimates of the survival function of a population. The general formula for
Kaplan-Meier estimates, as described by Kleinbaum and Klein (2012), is shown as
+ (, > $" |, ≥ $" )
!"($(") ) = !"($("$%) ) × )*
where the authors describe the estimate calculated with “survival estimate for a previous failure
time is multiplied by the conditional probability of surviving past the current failure time.”
Essentially, Kaplan-Meier curves generate survival probabilities and communicate to us visually
how one group’s survival compares to that of another group’s. Kaplan-Meier curves can be
tested for significance with the use of a log-rank test to determine if one group’s survival is truly
different from another group’s, as will be discussed in the results of our analyses.
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Following the creation of these Kaplan-Meier survival curves, statistical modeling of the
data is completed with the use of the Cox Proportional Hazards model (Cox PH). The Cox PH
model is a popular model used in survival analysis for its robust nature that can closely
approximate correct results for a variety of different data. The model itself can assess the
relationships of different covariates of interest with survival of an event by using a formula that
involves a baseline hazard function of time and an exponential function of covariates of interest.
The formula for the Cox PH model (Kleinbaum & Klein, 2012) is shown as:
(

ℎ($, 2) = ℎ& ($)345 67 8' 9' :
')%

where X = (X1, X2, …, Xp) are explanatory variables (covariates of interest) and h0(t) is the
baseline hazard function of time. From the formula, we can see how the hazard at a given time
for an individual is determined using explanatory variables of interest. To relate this formula to
our survival analysis, the hazard function generated from this formula will communicate the
likelihood that a patient will recover at a certain time, with explanatory variables such as
treatment type, age, sex, etc. taken into account. An important thing to note about the Cox PH
model is that it requires the satisfaction of the proportional hazards (PH) assumption. Checking
that a model meets the required PH assumption is the next step that will be taken in our model
fitting approach for this data.
For the PH assumption to be met, the hazard ratio must be independent of time or
constant over time. This means that one individual’s hazard rate is proportional to the hazard rate
of another individual. This is mathematically written (Kleinbaum & Klein, 2012) as
> (?, 2)
ℎ;($ , 2∗ ) = <;=
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where X* and X denote individuals and <; is a proportionality constant independent of time. To
determine that a fitted Cox PH model meets the PH assumption, options to verify the PH
assumption include graphical visualization of a constant hazard rate, goodness of fit statistical
testing methods, and creating an extended Cox PH model with time-dependent variables. To
verify the PH assumption graphically, we can check that the hazard curves of different groups of
an explanatory variable are proportional, or we can check that the log-log survival curves of the
variable do not cross one another; if either of these plots fail to show this proportionality or
parallelism, the PH assumption is not met. Additionally, goodness of fit statistical testing can be
performed on the explanatory variables to test for PH assumption satisfaction. Many testing
approaches exist that are based on Schoenfeld residuals. These tests check if the Schoenfeld
residuals for a covariate are uncorrelated with time in the model. If the p-value for these tests is
shown to be statistically significant, then the PH assumption is not met. Finally, if goodness of fit
testing has proven a covariate to be correlated with time, an extended Cox PH model that
accounts for this time-dependent variable can be fit, where the original variable is multiplied by a
function of time.
For the statistical analysis conducted in this study, a mixture of both R, a statistical
programming language, and SAS, a statistical software, were used to create Kaplan Meier
curves, conduct model fitting, and check model assumptions. Particularly, the data obtained from
NIAID was first cleaned in R to create new groups for the variables of “Race” and “Ethnicity.”
This data processing was performed to assist with downstream analysis and combined race
groups aside from “White” to “Other” or “Unknown.” Similarly, the ethnicity variable was
combined into “Hispanic or Latino,” “Not Hispanic or Latino,” or “Unknown.” Kaplan Meier
curves for time to recovery and time to death for the two different treatment groups were also

6
created with R, using the “survival” package and survfit() function to create survival curves,
along with the “survminer” package and the ggsurvplot() function to plot the created curves. The
remaining analysis, including model fitting and model checking, was performed in SAS. Cox PH
model fitting and assumption checking can be performed with the PROC PHREG procedure in
SAS. This PROC PHREG procedure involves the use of the model statement for model fitting
and the use of the zph command for goodness of fit testing on covariates.
Results
To follow the procedure for performing our survival analysis, the first step conducted was
obtaining Kaplan-Meier curves for our time to recovery data. We are primarily interested in if
the different treatment types, combination of drugs treatment or placebo treatment, has an effect
on patient time to recovery. The Kaplan-Meier curve generated for time to recovery for the
different treatment groups can be seen in Figure 1. From the Kaplan-Meier curves created, we
can see that the placebo group (indicated in blue) has a higher survival curve than that of the
combination group (indicated in red). While in a time to death model this would indicate that the
placebo group is better at achieving survival, in the case of our data, this means that the placebo
group is better at “surviving” recovery, indicating that the combination treatment group has
faster recovery times. The log-rank test statistic is indicated from our curves to be 0.017 (lower
left-hand corner), meaning the difference between the two Kaplan-Meier curves is significant
and the patient treatment group does influence patient time to recovery.
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Figure 1. Kaplan-Meier curves for time to recovery for patients receiving combination drug
treatment and those receiving placebo drug treatment.
After creating these Kaplan-Meier curves for our time to recovery data, we then want to
proceed with fitting a Cox PH model to check the parameter estimate and hazard ratio for the
treatment type effect. We fit a Cox PH model only including the treatment type covariate and test
the goodness of fit with the zph command in SAS. The results of the zph command indicate that
the treatment type variable is not significant (Appendix Figure 2), with a p-value of 0.3574. This
means that we can proceed with the Cox PH model that was fit and analyze the maximum
likelihood estimates generated from the model (Figure 2).
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Parameter
TRTP

Degrees
Of
Freedom
Baricitinib 1

Parameter Standard
Estimate Error

ChiSquare

Pr > ChiSquare

Hazard
Ratio

0.15777

5.200

0.0226

1.171

0.06919

+ RDV
Figure 2. Maximum Likelihood Estimates for Cox PH model including treatment type for time
to recovery data.
From our table of the maximum likelihood estimates, we find the treatment type variable
to be significant in our model (p-value 0.0226). The associated hazard ratio for this variable is
reported as 1.171 and the parameter estimate for the variable is 0.15777. These values indicate to
us that treatment type does have a significant effect on patient recovery time, particularly that
patient recovery time is positively impacted by the combination of drugs. Those patients in the
combination drug treatment group are associated with faster recovery times than those patients
receiving remdesivir alone.
Continuing with our analysis after fitting this initial Cox PH model, we want to build off
the model by adding in more covariates of interest. The covariates added to fit a new Cox PH
model are treatment type, age, sex, race, BMI, ethnicity, region, baseline duration of symptoms,
and a hypertension flag. Some covariates added to the model require a reference variable, which
is what their hazard ratios are interpreted as being in comparison to. Particularly, the race,
ethnicity, and region variables required reference groups which were, respectively, white
patients, Hispanic or Latino patients, and the North America region. After adding these
covariates to the model, we check the PH assumption with the zph command and find that the
Asia region fails to meet the PH assumption for our model, indicated with a p-value less than
0.0001 (Appendix Figure 3). Failing to meet the PH assumption then requires us to go back to
the Cox PH model and adjust it to ensure that the PH assumption is met.
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To correct our model for the Asia region to meet the PH assumption, we fit an extended
Cox PH model. This extended model will include a time-dependent variable for the covariate
that fails the PH assumption, in our case this is the Asia region variable. An extended Cox PH
model with a log-time dependent Asia region variable is then fit. This new variable will measure
the interaction of the Asia region with time, thus satisfying the PH assumption. Proceeding with
the Cox PH model maximum likelihood estimates, we then interpret the hazard ratio for both the
Asia and Asiat variables as expressed as a function of time rather than the values that directly
appear in the table (Figure 3). The hazard ratio for the Asia region can be expressed with this
equation
@A = 345{−3.93678 + 1.65690NOP($)}
that shows that as time increases in the study, the hazard ratio for the Asia region in comparison
to the North America region increases with time. In looking at the remaining results in the table,
the variables of treatment type, age, unknown ethnicity, and baseline duration of symptoms are
all significant in the model. Age and unknown ethnicity were associated negatively with
recovery time, while treatment type and baseline duration of symptoms are associated positively
with recovery time.
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Parameter
TRTP

Baricitinib +

Degrees Parameter Standard
Of
Estimate Error
Freedom
1
0.15367
0.07125

ChiSquare

Hazard
Ratio

4.6563

Pr >
ChiSquare
0.0309

1

-0.02049

0.00288

50.6064

<.0001

0.980

1.166

RDV
AGE
SEX

F

1

0.14424

0.07566

3.6345

0.0566

1.155

RACE3

OTHER

1

-0.07279

0.10521

0.4786

0.4890

0.930

RACE3

UNKNOWN 1

0.09429

0.09867

0.9132

0.3393

1.099

1

0.00175

0.00447

0.1530

0.6956

1.002

1

0.14596

0.09970

2.1433

0.1432

1.157

UNKNOWN 1

-0.68660

0.30987

4.9096

0.0267

0.503

Asia

1

-3.93678

0.67446

34.0693

<.0001

0.020

asiat

1

1.65690

0.28029

34.9433

<.0001

5.243

Europe

1

0.14261

0.29502

0.2337

0.6288

1.153

BDURSYMP

1

0.01863

0.00805

5.3566

0.0206

1.019

1

-0.00173

0.08021

0.0005

0.9828

0.998

BMI
ETHNIC3

NOT
HISPANIC
OR
LATINO

ETHNIC3

HYPFL

N

Figure 3. Maximum Likelihood Estimates for time to recovery data with added covariates.
Having conducted the analysis for our initial interest of study with this data, we also are
interested in analyzing the relationships that might exist between patient time to death and
treatment type. The analysis for this time to death data will closely follow our analysis for the
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time to recovery data. We begin with fitting Kaplan-Meier curves for the different treatment
groups. In looking at the Kaplan-Meier curves created (Figure 4), we find that the combination
drug group (indicated in red) does have a higher survival curve than the placebo group (indicated
in blue). This would suggest a lower likelihood of dying with the combination treatment, but the
log-rank test statistic indicates that the difference between the two survival curves is not
significant. From the formal analysis, we cannot conclude that the time to a patient’s death is
affected by the treatment type received in the clinical trial.

Figure 4. Kaplan-Meier curves for treatment type groups using time to death data.
After the creation of these Kaplan-Meier curves, we still proceed on with Cox PH model
fitting. For our first time to death model, we include only the treatment type variable. The
goodness of fit testing conducted on this model shows that the model meets the PH assumption
(Appendix Figure 4). In looking at the maximum likelihood estimates for this model (Figure 5),
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however, we note that just as in our Kaplan-Meier curves, treatment type is not significant and
thus, treatment type is not associated with death for a patient.
Parameter
TRTP

Degrees
Of
Freedom
Baricitinib 1

Parameter Standard
Estimate Error

ChiSquare

Pr > ChiSquare

Hazard
Ratio

-0.45177

2.9709

0.0848

0.636

0.26210

+ RDV
Figure 5. Maximum Likelihood Estimates for time to death data with treatment group variable.
Fitting a second Cox PH model with all covariates added that existed in the second model
of our time to recovery data, we find that all covariates satisfy PH assumption testing (Appendix
Figure 5). Then analyzing the table of maximum likelihood estimates for this model, we see that
all of the covariates, aside from age, are insignificant in the model (Figure 6). Age being
significant in the model and its positive parameter estimate of 0.05527 indicate that those
patients with a higher age are associated with higher risk of dying. The remaining results of
insignificant covariates tells us that other patient characteristics do not put them at a higher risk
of death.
Parameter
TRTP

Baricitinib +

Degrees Parameter Standard
Of
Estimate Error
Freedom
1
-0.34864 0.26668

ChiSquare

1

0.05527

0.01208

20.9410 <.0001 1.057

1.7091

Pr >
ChiSquare
0.1911

Hazard
Ratio
0.706

RDV
AGE
SEX

F

1

0.02831

0.27914

0.0103

0.9192

1.029

RACE3

OTHER

1

-0.24083

0.36785

0.4286

0.5127

0.786
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RACE3

UNKNOWN 1

-0.03174

0.37688

0.0071

0.9329

0.969

1

0.01321

0.01991

0.4399

0.5072

1.013

1

0.32633

0.35480

0.8460

0.7531

1.391

ETHNIC3

UNKNOWN 1

0.32994

1.04908

0.0989

0.7531

1.391

REGION

Asia

1

-1.24749

1.05043

1.4104

0.2350

0.287

REGION

Europe

1

-

674.27595 0.0004

0.9849

0.000

BMI
ETHNIC3

NOT
HISPANIC
OR
LATINO

12.72828
BDURSYMP
HYPFL

N

1

-0.00214

0.02854

0.0056

0.9401

0.998

1

-0.03115

0.30441

0.0105

0.9185

0.969

Figure 6. Maximum Likelihood Estimates for time to death data with added covariates.
Discussion
After this analysis, a few results from the data are of interest. To begin with the time to
recovery analysis, the biggest finding is that the combination of remdesivir and baricitinib is a
superior treatment to remdesivir alone for improving recovery time among patients. This finding
is a vital breakthrough in identifying possible treatments for COVID-19. Currently, very few
treatment options or cures are available for the disease, which is why the widespread impact of
the disease has had a great effect for so long in our society. Finding options for treatments with
the usage of clinical trials and statistical analysis offers promising directions for combatting
COVID-19 in the future.
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Secondary findings of the time to recovery analysis include how age and unknown
ethnicity lead to longer recovery times. For patients of older ages, their hazard ratio indicates that
their recovery periods are longer than those of a younger age. Similarly, patients with unknown
ethnicity also are associated with longer recovery times as compared to patients of Hispanic or
Latino descent. Interestingly, the baseline duration of symptoms, how many days a patient had
symptoms prior to entering the study and receiving treatment, is associated with shorter recovery
times as the number of days increases. Also, as noted in our extended Cox PH model, the Asia
region must be represented with a time-dependent variable in our model. This informs us that the
hazard ratio for the Asia region changes over time, and particularly increases over the study
period as compared to the North America region. From looking at our Cox PH model overall, we
see that many of the variables do not have hazard ratios much higher or lower than 1, which
indicates that the clinical trial found consistent results across the different patient demographics.
Then looking at the time to death analysis, most of our results indicate that a patient’s
time to death is not associated with the different variables included in our models. The only
significant covariate for the time to death models was age, which indicated that a higher age is
associated with a higher risk of dying. The lack of significant results in these Cox PH models
does indicate something positive, however, which is that treatment types are not associated with
patient death. Additionally, the other covariates in the model also imply that a risk of death is not
increased for any particular group of patients.
Conclusion
The results of our analysis indicate exciting results: the testing of these clinical trial drug
treatments is significant and a combination of drugs yields better recovery times for patients as
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compared to a singular drug. This conclusion was also found in an analysis of the data performed
by the clinical trial research group associated with NIAID (Kalil et al., 2021). The results of this
project also highlight interesting relationships that exist between different covariates of our
events of interest. It is these relationships that make survival analysis so valuable as they can
communicate to us any vulnerable populations that exist and a society and any underlying factors
that healthcare may not be taking into account. Having knowledge of these relationships is what
allows for future work to be done in public health reform.
COVID-19 and how it has affected the world has revealed many disparities amongst
different groups in society. Research on how different demographics are affected by the disease
indicate that those of lower-income backgrounds and minority status are at increased risk of
being infected and impacted by COVID-19 (Aldridge et al. 2020; Khanijahani, 2020;
Khanijahani et al. 2020; Paul et al., 2021). This research shows areas of weakness in healthcare
that should be fixed. Being able to directly show if these relationships exist between patient
socioeconomic status and a patient’s death from COVID-19 offers valuable insight into how
society functions and how improvements could be made to better the lives of all in a society.
Unfortunately, obtaining data with the information on different social determinants of
heath can be difficult to come by. Often, a patient’s income level or other identity characteristics
are not indicated in data taken at the patient level. There has been a push for healthcare data to
consider this information (Khalatbari-Soltani et al, 2020; Rogawski et al., 2016). Including such
information offers a more holistic approach to data analysis and again, gives us the possibility of
identifying interesting relationships that may exist. This area of public health research can make
a large impact on societal health and how healthcare is structured in the future.
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Appendix
Variable

RECCNSR

DTHCNSR

TRTP

Frequency

Percent

Cumulative

Cumulative

Frequency

Percent

0

839

81.22

839

81.22

1

194

18.78

1033

100.00

0

61

5.91

61

5.91

1

972

94.09

1033

100.00

Baricitinib +

515

49.85

515

49.85

518

50.15

1033

100.00

F

381

36.88

381

36.88

M

652

63.12

1033

100.00

OTHER

278

26.91

278

26.91

UNKNOWN

259

25.07

537

51.98

WHITE

496

48.02

1033

100.00

HISPANIC

531

51.40

531

51.40

486

47.05

1017

98.45

16

1.55

1033

100.00

RDV
Placebo +
RDV
SEX

RACE3

ETHNIC3

OR LATINO
NOT
HISPANIC
OR LATINO
UNKNOWN

19
REGION

Asia

67

6.49

67

6.49

Europe

13

1.26

80

7.74

North

953

92.26

1033

100.00

America
Appendix Figure 1. Frequency table for covariates in time to recovery and time to death
models.
Transform Predictor Variable

Correlation ChiSquare Pr >

t

Pr > |t|

ChiSquare Value
RANK

TRTPBaricitinib_RDV 0.0318

0.8472

0.3574

0.92

0.3580

Appendix Figure 2. Goodness of fit zph testing results for treatment variable in time to recovery
model.
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Transform Predictor Variable

Pr >
ChiSquare

RANK

TRTPBaricitinib_RDV

0.2504

RANK

AGE

0.7333

RANK

SEXF

0.8552

RANK

RACE3OTHER

0.4957

RANK

RACE3UNKNOWN

0.0927

RANK

BMI

0.6658

RANK

ETHNIC3NOT_HISPANIC_OR_LATINO 0.5321

RANK

ETHNIC3UNKNOWN

0.4799

RANK

REGIONAsia

<.0001

RANK

REGIONEurope

0.8914

RANK

BDURSYMP

0.9789

RANK

HYPFLN

0.7860

Appendix Figure 3. Goodness of fit zph testing results for covariates of interest in time to
recovery model.
Transform Predictor Variable

Correlation ChiSquare Pr >

t

Pr > |t|

ChiSquare Value
RANK

TRTPBaricitinib_RDV 0.0304

0.0564

0.8123

Appendix Figure 4. Goodness of fit zph testing results

0.23

0.8160
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Transform Predictor Variable

Pr >
ChiSquare

RANK

TRTPBaricitinib_RDV

0.9687

RANK

AGE

0.6470

RANK

SEXF

0.7442

RANK

RACE3OTHER

0.8850

RANK

RACE3UNKNOWN

0.1179

RANK

BMI

0.1813

RANK

ETHNIC3NOT_HISPANIC_OR_LATINO 0.1539

RANK

ETHNIC3UNKNOWN

0.5237

RANK

REGIONAsia

0.1340

RANK

REGIONEurope

0.9998

RANK

BDURSYMP

0.2960

RANK

HYPFLN

0.9353

Appendix Figure 5. Goodness of fit zph testing results for covariates of interest in time to death
model.
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R CODE
### Survival Analysis Coding Framework ##
#Load packages
library(survminer) #for clean plotting
library(survival) #for survival analysis functions
#Load dataset and read in data
setwd("/Users/fernandamontoya/Desktop/ACTT2_Datasets/ACTT_2_original")
covidData <- read.csv(file="ACTT2.csv",)
head(covidData)
#Creating column for recovery event
covidData$EVENTR <- ifelse(covidData$RECCNSR == 0, 1, 0)
#Column for death event
covidData$EVENTD <- ifelse(covidData$DTHCNSR == 0, 1, 0)
head(covidData)
#Create new column for three race categories (White, Other, Unknown)
covidData$RACE3 <- ifelse(covidData$RACE == "WHITE", "WHITE",
ifelse(covidData$RACE == "UNKNOWN", "UNKNOWN", "OTHER"))
#Create new column for three ethnicity categories (Hispanic or Latino, Not, Unknown)
covidData$ETHNIC3 <- ifelse(covidData$ETHNIC == "HISPANIC OR LATINO",
"HISPANIC OR LATINO", ifelse(covidData$ETHNIC == "NOT HISPANIC OR LATINO",
"NOT HISPANIC OR LATINO", "UNKNOWN"))
#export cleaned data to .csv file to use in SAS
write.csv(covidData,
"/Users/fernandamontoya/Desktop/ACTT2_Datasets/ACTT_2_original/ACTT2_clean.csv", na =
"", row.names=FALSE)
#Define variables
timeR <- covidData$TTRECOV
timeD <- covidData$TTDEATH
eventR <- covidData$EVENTR
eventD <- covidData$EVENTD
group <-covidData$TRTP
#Kaplan-Meier non-parametric analysis by treatment for RECOVERY
kmsurvival2 <- survfit(Surv(timeR,eventR) ~ group)
ggsurvplot(kmsurvival2, data=covidData, risk.table=TRUE, conf.int=TRUE, pval=TRUE,
pval.method=TRUE, ggtheme=theme_minimal())
#Kaplan-Meier non-parametric analysis by treatment for DEATH
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kmsurvival3 <- survfit(Surv(timeD,eventD) ~ group)
ggsurvplot(kmsurvival3, data=covidData, risk.table=TRUE, conf.int=TRUE, pval=TRUE,
pval.method=TRUE, ggtheme=theme_minimal())
SAS CODE
libname mydata \\Client\C$\Users\ fernandamontoya\ Desktop\ACIT2 Datasets\ACIT 2
original\;
*read data;
data covid;
set mydata.actt2_clean;
run;
data covid2;
set covid;
Europe=0;
Asia=0;
if region='Asia' then Asia=1;
if region='Europe' then Europe=1;
run;
proc freq data=covid:
tables reccnsr dthcnsr sex race3 ETHNIC3 region trtp;
run;
*Step 1: model treatment w/o interaction*;
proc phreg data=covid zph;
class trtp;
model ttrecov*reccnsr(1)=trtp;
hazardratio "trt" trtp:
run;
*Step 2: final model of added covariates*;
proc phreg data=covid zph;
class trtp Sex Race3 (ref='WHITE') ETHNIC3 (ref='HISPANIC OR LATINO') region
(ref='North America') hypfl stratum;
model ttrecov*reccnsr (1) =trtp Age Sex race3 BMI ETHNIC3 Region bdursymp hypfl;
strata stratum;
hazardratio
"trt" trtp;
run;
* Step 3: Time to death model w/ treatment variable*
proc phreg data=covid zph:
class trtp;
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model ttdeath*dthcnsr(1)=trtp:
hazardratio "trt" trtp;
run;
* Step 4: model for time to death with covariates *;
proc phreg data=covid zph:
class trtp sex race3 (ref='WHITE' ) ethnic3 (ref='HISPANIC OR LATINO') region (ref='North
America' ) hypfl stratum;
model ttdeath*dthcnsr (1)=trtp age sex race3 BMI ethnic3 region bdursymp hypfl;
strata stratum;
hazardratio "trt" trtp;
run:
/*Using log time for asia region (Extend Cox PH model)*/
proc phreg data=covid2 zph;
class trtp Sex Race3 (ref='WHITE') Ethnic3 (ref='HISPANIC OR LATINO') hypfl stratum;
model ttrecov*reccnsr (1) =trtp Age Sex race3 BMI Ethnic3 Asia asiat Europe bdursymp hypfl:
asiat=asia*log(ttrecov):
strata stratum:
hazardratio "trt" trtp;
run;

